Blood Pressure Monitor

Start Of Phase 2a Clinical Study Of Angiotensin Therapeutic Vaccine In Hypertension
Protherics PLC "Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, today announces that the first patient has been enrolled in a phase 2a study of its Angiotensin Therapeutic Vaccine (ATV) for the treatment of hypertension.

Study Links High Normal Blood Pressure To Significant Cardiovascular Risk - Atcor Medical's SphygmoCor System Plays Key Role In Discovery
A new study of more than 10,000 patients, conducted by the Universities of Cambridge and Cardiff in the United Kingdom using AtCor Medical Holdings Limited's SphygmoCor® has found that more than 70 percent of patients identified as having 'high-normal' systolic blood pressure through traditional cuff blood pressure measurement may be at serious cardiovascular risk.

Teva Announces Tentative Approval Of Generic Diovan(R) Tablets
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' hypertension treatment Diovan® (Valsartan) Tablets, 40 mg, 80 mg, 160 mg and 320 mg.